Related Experiment Video
Updated: May 6, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
Inflammatory stress induces statin resistance by disrupting 3-hydroxy-3-methylglutaryl-CoA reductase feedback
Yaxi Chen1, Halcyon Ku, Lei Zhao
1From the Key Laboratory of Metabolism on Lipid and Glucose, Centre for Lipid Research, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China (Y.C., L.Z., Q.L., A.H., X.Z.R.); Division of Nephrology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan (L.C.L.); and John Moorhead Research Laboratory, Centre for Nephrology, University College London (UCL) Medical School, United Kingdom (H.K., D.C.W., Z.V., J.F.M., S.H.P., X.Z.R.).
Insights
Chronic inflammation increases cardiovascular disease risk and may cause statin resistance by boosting cholesterol synthesis via HMGCoA-R. This study found inflammatory stress weakens statin effectiveness, potentially explaining lipid accumulation and treatment failure.
Area of Science:
- Cardiovascular Science
- Molecular Biology
- Pharmacology
Background:
- Chronic inflammatory states significantly elevate cardiovascular disease risk.
- Standard statin doses may offer reduced cardiovascular protection in inflamed patients.
- Inflammation-induced increases in cholesterol synthesis might be resistant to statins.
Purpose of the Study:
- To investigate if inflammation-induced 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCoA-R) cholesterol synthesis is statin-resistant.
- To determine if the sterol regulatory element binding protein cleavage-activating protein (SREBP-CA) pathway mediates this statin resistance.
Main Methods:
- Induced inflammation in vitro (cytokines, LPS) and in vivo (triple knockout mice).
- Assessed HMGCoA-R mRNA, protein, and enzymatic activity.
- Utilized atorvastatin, SREBP-CA knockdown, and overexpression to study pathway involvement.
- Measured serum cholesterol and aortic lipid accumulation in mice.
Main Results:
- Inflammatory stress exacerbated cholesterol ester accumulation and increased HMGCoA-R expression via SREBP-CA/SREBP-2.
- Atorvastatin's inhibition of HMGCoA-R activity and cholesterol synthesis was reduced under inflammatory conditions.
- SREBP-CA knockdown prevented statin resistance; its overexpression induced resistance.
- Higher atorvastatin doses were required in vivo to reduce cholesterol and lipids during inflammation.
Conclusions:
- Elevated HMGCoA-R-mediated cholesterol synthesis under inflammation is a key mechanism for intracellular lipid accumulation.
- This pathway contributes to statin resistance in inflammatory states.
Objective:
The risk of cardiovascular disease is increased by up to 33 to 50× in chronic inflammatory states and convention doses of statins may not provide the same cardiovascular protection as in noninflamed patients. This study investigated whether the increase in 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCoA-R)-mediated cholesterol synthesis observed under inflammatory stress was resistant to the action of statins and if so, whether this was because of interference with the sterol regulatory element binding protein cleavage-activating protein pathway.
Approach And Results:
Inflammatory stress was induced by adding cytokines (interleukin-1β, tumor necrosis factor-α, and interleukin-6) and lipopolysaccharides to vascular smooth muscle cells in vitro and by subcutaneous casein injection in apolipoprotein E/scavenger receptors class A/CD36 triple knockout mice in vivo. Inflammatory stress exacerbated cholesterol ester accumulation and was accompanied in vitro and in vivo by increased HMGCoA-R mRNA and protein expression mediated via activation of the sterol regulatory element binding protein cleavage-activating protein/sterol regulatory element binding protein-2 pathway. Atorvastatin reduced HMGCoA-R enzymatic activity and intracellular cholesterol synthesis in vitro. However, inflammatory stress weakened these suppressive effects. Atorvastatin at concentrations of 16 μmol/L inhibited HMGCoA-R activity by 50% in vascular smooth muscle cells, but the same concentration resulted in only 30% of HMGCoA-R activity in vascular smooth muscle cells in the presence of interleukin-1β. Knocking down sterol regulatory element binding protein cleavage-activating protein prevented statin resistance induced by interleukin-1β, and overexpression of sterol regulatory element binding protein cleavage-activating protein induced statin resistance even without inflammatory stress. In vivo, the amount of atorvastatin required to lower serum cholesterol and decrease aortic lipid accumulation rose from 2 to 10 mg/kg per day in the presence of inflammatory stress.
Conclusions:
Increased cholesterol synthesis mediated by HMGCoA-R under inflammatory stress may be one of the mechanisms for intracellular lipid accumulation and statin resistance.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Inflammation
Atherosclerosis III: Management
Cholesterol: Significance and Regulation
Considering cholesterol and...
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Atherosclerosis I: Introduction
